scispace - formally typeset
Y

Yutaka Suzuki

Researcher at University of Tokyo

Publications -  875
Citations -  42146

Yutaka Suzuki is an academic researcher from University of Tokyo. The author has contributed to research in topics: Gene & Medicine. The author has an hindex of 85, co-authored 767 publications receiving 35471 citations. Previous affiliations of Yutaka Suzuki include Japan Agency for Medical Research and Development & Institute for the Physics and Mathematics of the Universe.

Papers
More filters
Journal ArticleDOI

Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer

TL;DR: In this article, the essential role of disease phase-specific TF collaboration changes in advanced prostate cancer (PC) was investigated and OCT4 was identified as a key TF in the disease pathology.
Journal ArticleDOI

Cell cycle arrest determines adult neural stem cell ontogeny by an embryonic Notch-nonoscillatory Hey1 module.

TL;DR: In this article, the authors demonstrate that Notch and an effector Hey1 form a module that is upregulated by cell cycle arrest in slowly dividing neural stem cells (NSCs).
Journal ArticleDOI

Functional divergence of duplicate genes several million years after gene duplication in Arabidopsis.

TL;DR: Interestingly, it was found that functional divergence of duplicated genes was accelerated several million years after gene duplication compared with immediately before gene duplication, and positive and purifying selection in the A. halleri lineages tended to have a higher proportion of positive selection compared with non-duplicated genes.
Journal ArticleDOI

Foxr2 promotes formation of CNS-embryonal tumors in a Trp53-deficient background.

TL;DR: The data demonstrate that Foxr2 plays a causative role in the formation of CNS-embryonal tumors and gene expression profiling revealed that OB and BS tumor cells were enriched for the expression of the genes specific to CNS NB-FOXR2.
Journal Article

Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.

TL;DR: It is demonstrated here that tumor cells genetically modified to secrete IL-2 can enhance the precursor response in the tumor-bearing host and subsequently augment the antitumor efficacy of adoptive immunotherapy.